3rd Quarter - Report
SIDLEY AUSTIN LLP for GW PHARMA INC.
Firm
Client
Income
$180,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDA and DEA regulation of cannabidiol; support of and technical changes to S. 481 (Improving Regulatory Transparency for New Medical Therapies Act); S. 1333 (Therapeutic Hemp Medical Access Act of 2015)
Foreign entity interest: GW Pharma Plc has 100% ownership of GW Pharma Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA LOUISE DELOATCHE | Health Policy Director; Sen. Orrin Hatch; Chief of Staff, Legislative Director, and Legislative Assistant for Rep. Mike Bilirakis |
| PETER M GOODLOE | Legislative Counsel, House Energy & Commerce; Legislative Counsel, House Office of Legislative |
| DORA HUGHES | Deputy Director of Health, HELP, Sen. Edward Kennedy; Health Policy Advisor, Sen. Barak Obama, Counselor for Science and Public Health, HHS |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.